Bioxcel Receives Second Positive Recommendation To Continue Phase 3 Trial For Treatment Of Agitation Associated With Schizophrenia

BioXcel Therapeutics Inc BTAI:

• BIOXCEL THERAPEUTICS RECEIVES SECOND POSITIVE RECOMMENDATION FROM DATA SAFETY MONITORING BOARD (DSMB) TO CONTINUE SERENITY AT-HOME PIVOTAL PHASE 3 SAFETY TRIAL FOR ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR DISORDERS OR SCHIZOPHRENIA

• BIOXCEL THERAPEUTICS INC - TOPLINE DATA FOR SERENITY AT-HOME TRIAL EXPECTED IN Q3 2025

• BIOXCEL THERAPEUTICS INC - DSMB RECOMMENDS CONTINUATION OF SERENITY AT-HOME TRIAL